These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 32844745)

  • 1. PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response.
    Kim C; Wang XD; Yu Y
    Elife; 2020 Aug; 9():. PubMed ID: 32844745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
    Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
    Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of PARP1 Dampens Pseudorabies Virus Infection through DNA Damage-Induced Antiviral Innate Immunity.
    Li GL; Ding GX; Zeng L; Ming SL; Fu PF; Wang Q; Yang GY; Wang J; Chu BB
    J Virol; 2021 Jul; 95(16):e0076021. PubMed ID: 34037418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP trapping is governed by the PARP inhibitor dissociation rate constant.
    Gopal AA; Fernandez B; Delano J; Weissleder R; Dubach JM
    Cell Chem Biol; 2024 Jul; 31(7):1373-1382.e10. PubMed ID: 38262416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation.
    Wang S; Han L; Han J; Li P; Ding Q; Zhang QJ; Liu ZP; Chen C; Yu Y
    Nat Chem Biol; 2019 Dec; 15(12):1223-1231. PubMed ID: 31659317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avoid the trap: Targeting PARP1 beyond human malignancy.
    Kim C; Chen C; Yu Y
    Cell Chem Biol; 2021 Apr; 28(4):456-462. PubMed ID: 33657415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicity.
    Chen HD; Chen CH; Wang YT; Guo N; Tian YN; Huan XJ; Song SS; He JX; Miao ZH
    Int J Cancer; 2019 Aug; 145(3):714-727. PubMed ID: 30675909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo.
    Shao Z; Lee BJ; Rouleau-Turcotte É; Langelier MF; Lin X; Estes VM; Pascal JM; Zha S
    Nucleic Acids Res; 2020 Sep; 48(17):9694-9709. PubMed ID: 32890402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP1 inhibitors induce pyroptosis via caspase 3-mediated gasdermin E cleavage.
    Kim C; Wang XD; Jang S; Yu Y
    Biochem Biophys Res Commun; 2023 Feb; 646():78-85. PubMed ID: 36706709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance.
    Kanev PB; Atemin A; Stoynov S; Aleksandrov R
    Semin Oncol; 2024; 51(1-2):2-18. PubMed ID: 37714792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP mediated DNA damage response, genomic stability and immune responses.
    Zong C; Zhu T; He J; Huang R; Jia R; Shen J
    Int J Cancer; 2022 Jun; 150(11):1745-1759. PubMed ID: 34952967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders.
    Peng X; Li Y; Qu J; Jiang L; Wu K; Liu D; Chen Y; Peng J; Guo Y; Cao X
    Eur J Med Chem; 2024 May; 271():116405. PubMed ID: 38678823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib.
    Ding X; Zhu Z; Lapek J; McMillan EA; Zhang A; Chung CY; Dubbury S; Lapira J; Firdaus S; Kang X; Gao J; Oyer J; Chionis J; Rollins RA; Li L; Niessen S; Bagrodia S; Zhang L; VanArsdale T
    Sci Rep; 2022 Jul; 12(1):12501. PubMed ID: 35864202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the PARP1, ADP-Ribosylation, and TRIP12 Triad With Markers of Patient Outcome in Human Breast Cancer.
    Krishnan A; Spegg V; Dettwiler S; Schraml P; Moch H; Dedes K; Varga Z; Altmeyer M
    Mod Pathol; 2023 Jul; 36(7):100167. PubMed ID: 36990278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
    Chabanon RM; Muirhead G; Krastev DB; Adam J; Morel D; Garrido M; Lamb A; Hénon C; Dorvault N; Rouanne M; Marlow R; Bajrami I; Cardeñosa ML; Konde A; Besse B; Ashworth A; Pettitt SJ; Haider S; Marabelle A; Tutt AN; Soria JC; Lord CJ; Postel-Vinay S
    J Clin Invest; 2019 Mar; 129(3):1211-1228. PubMed ID: 30589644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer.
    Liu C; Li J; Xu F; Chen L; Ni M; Wu J; Zhao H; Wu Y; Li J; Wu X; Chen X
    Mol Cancer; 2024 May; 23(1):111. PubMed ID: 38778348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells.
    Kanev PB; Varhoshkova S; Georgieva I; Lukarska M; Kirova D; Danovski G; Stoynov S; Aleksandrov R
    Cell Rep; 2024 May; 43(5):114234. PubMed ID: 38758646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in
    Li P; Zhen Y; Kim C; Liu Z; Hao J; Deng H; Deng H; Zhou M; Wang XD; Qin T; Yu Y
    Sci Adv; 2023 Oct; 9(43):eadg7752. PubMed ID: 37878693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency.
    McLaughlin LJ; Stojanovic L; Kogan AA; Rutherford JL; Choi EY; Yen RC; Xia L; Zou Y; Lapidus RG; Baylin SB; Topper MJ; Rassool FV
    Proc Natl Acad Sci U S A; 2020 Jul; 117(30):17785-17795. PubMed ID: 32651270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.